Recombinant Human KLK9 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2779



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human KLK9 protein His16-Asn250 (Accession# Q9UKQ9-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 284366
Accession Q9UKQ9-1
PredictedSize 52.0 kDa
SDS-PAGE 58-68 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

KLK9, or kallikrein-related peptidase 9, is a member of the human kallikrein-related peptidases family, which is the largest family of secreted serine proteases. These enzymes have diverse expression patterns and physiological roles, and their aberrant activity has been linked to various pathologies such as respiratory diseases, neurodegeneration, skin-barrier dysfunction, and cancer. The serum level of KLK9 has also been suggested to have the potential to be used as a biomarker for asthma. The KLK9 gene was also found to be regulated by steroid hormones, mainly estrogens and progestins, in cancer cell lines.

References:

1. Filippou P, et al. (2017). Clin Proteomics.17;14:4. 2. Yousef GM, et al. (2003). Breast Cancer Res Treat. 78(2):149-58.